These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11451214)

  • 1. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.
    Püchler K; Laeis P; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S41-8. PubMed ID: 11451214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
    Malacco E; Omboni S; Mallion JM; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
    Omboni S; Malacco E; Mallion JM; Volpe M
    Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.
    Rana R; Singh A
    J Assoc Physicians India; 2010 Feb; 58():77-83. PubMed ID: 20653147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
    Ball KJ; Williams PA; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S49-56. PubMed ID: 11451215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and tolerability of olmesartan.
    Brunner HR
    Clin Ther; 2004; 26 Suppl A():A28-32. PubMed ID: 15291377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.
    Neutel J; Elliott WJ; Izzo J; Chen CL; Masonson H
    J Clin Hypertens (Greenwich); 2002; 4(5):325-31. PubMed ID: 12368570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan medoxomil.
    Warner GT; Jarvis B
    Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
    Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
    Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
    Wang JG; Sun NL; Ke YN; Zhang BH; Ikegami N; Zhu JR
    Clin Drug Investig; 2012 Nov; 32(11):729-34. PubMed ID: 23018282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
    Yoshida K; Kohzuki M
    Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.
    Sellin L; Stegbauer J; Laeis P; Rump LC
    J Hypertens; 2005 Nov; 23(11):2083-92. PubMed ID: 16208152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.